0.9632563267	calcium chloride
0.9627292586	hemolytic anemia
0.9614277894	uric acid
0.9613278354	visual field
0.9593902965	folic acid
0.9577232005	status epilepticus
0.9549783142	diabetic nephropathy
0.9535815878	myocardial infarction
0.9520858384	oxidative stress
0.9507391589	neuroleptic malignant syndrome
0.9479095207	breast cancer
0.9450914455	spinal cord
0.9420356284	rheumatoid arthritis
0.9349462648	heart failure
0.9330586428	heart rate
0.9278892344	blood pressure
0.9273828563	renal failure
0.9254579366	qt interval
0.9215991110	acute liver failure
0.9174529266	confidence interval
0.9157889312	acute renal failure
0.9134777876	nephrotic syndrome
0.9089752111	nitric oxide
0.9062439981	mm hg
0.9046798225	hemorrhagic cystitis
0.9030341773	cardiac arrest
0.8987984401	bone marrow
0.8977026099	ng ml
0.8921238478	liver failure
0.8905436750	glyceryl trinitrate
0.8895485324	puromycin aminonucleoside
0.8864595995	vascular resistance
0.8762417336	renal function
0.8741829039	coronary artery disease
0.8736177959	mg m2
0.8637246866	coronary artery
0.8567061807	receptor antagonist
0.8429068720	combination therapy
0.8393702475	case report
0.8381229604	optic neuropathy
0.8356093737	micrograms kg
0.8274058254	life threatening
0.8247325924	left ventricular
0.8223018765	blood flow
0.8176788144	passive avoidance
0.8145846020	high doses
0.8137625379	clinical trial
0.8098299746	adverse effects
0.8081814510	wistar rats
0.8020010962	heart disease
0.7919660888	growth factor
0.7907654620	sprague dawley
0.7664934549	double blind
0.7601322976	mg per deciliter
0.7575346720	muscle rigidity
0.7554201254	serotonin reuptake
0.7530840201	long term
0.7500707375	l dopa
0.7498880805	myocardial ischemia
0.7405099214	body weight
0.7382125934	serum creatinine
0.7376778836	statistically significant
0.7297786116	significant increase
0.7279588232	intravenous ribavirin
0.7261467774	torsade de pointes
0.7251378103	placebo controlled
0.7232877167	severe adenovirus
0.7226684232	mg kg i.v
0.7217337180	short term
0.7216853065	adenovirus disease
0.7208234284	death
0.7187276617	prostaglandin
0.7159132573	superoxide
0.7120975044	risk factors
0.7114665806	general
0.7114665806	extrapyramidal
0.7055694758	local
0.7049066182	physical
0.7030860181	arterial pressure
0.7011621838	eye
0.7010010389	hypersensitivity
0.6988196576	trials
0.6975712497	cognitive
0.6963573264	skin
0.6956940762	antiarrhythmic
0.6954756614	endometrial
0.6951423294	abdominal
0.6936288629	glomerular
0.6936288629	thrombosis
0.6930939340	male rats
0.6926869368	increased risk
0.6925380133	adenosine
0.6916959073	adverse events
0.6895255078	stroke
0.6893502601	white
0.6877488044	cystitis
0.6865541755	standard
0.6858777024	disorders
0.6856493347	atrial
0.6852508943	anesthesia
0.6851518810	anti
0.6838088361	diabetes
0.6820985907	microg kg
0.6820481219	adenovirus
0.6818836669	cessation
0.6812200638	grade
0.6810676887	vitamin
0.6798013488	p450
0.6793322815	sinus
0.6791524516	mitochondrial
0.6789488425	dna
0.6789006987	sprague dawley rats
0.6783124525	prospective study
0.6772623723	immune
0.6770375917	marrow
0.6762435098	basal
0.6752031349	secondary
0.6747235444	reverse
0.6745278219	state
0.6743406103	creatinine
0.6742262991	delivery
0.6737981929	relative
0.6731677519	performance
0.6723876474	man
0.6711545405	hospital
0.6711334562	thrombocytopenia
0.6710229124	cortex
0.6705244770	data suggest
0.6696937789	e2
0.6695869934	activated
0.6686834259	mental
0.6686834259	depression
0.6686040263	carcinoma
0.6677146043	hemorrhage
0.6677146043	biopsy
0.6666341311	activities
0.6659945537	scale
0.6659533352	dopamine
0.6656151553	cb 3717
0.6653169017	inflammatory
0.6651749790	acetylcholine
0.6648985679	pulmonary
0.6643639211	virus
0.6643639211	states
0.6641540287	internal
0.6640834426	platelet
0.6640311135	serotonin
0.6635994067	assessment
0.6635264676	oxygen
0.6634919468	epilepsy
0.6631813953	edema
0.6624904531	adverse effect
0.6624383788	delayed
0.6623925887	drinking
0.6622050081	metabolic
0.6622050081	event
0.6620166901	management
0.6611925865	carotid
0.6609976492	direct
0.6602483742	testing
0.6600110476	series
0.6599076088	arrhythmias
0.6597825982	essential
0.6597825982	fluid
0.6595721101	area
0.6592134539	density
0.6590557797	headache
0.6590006662	medical
0.6589822424	hypothesis
0.6589469448	ratio
0.6588437619	lithium
0.6588248824	order
0.6586588702	examination
0.6584321884	molecular
0.6584118076	estradiol
0.6584118076	autoimmune
0.6582590917	sexual
0.6581820740	abuse
0.6579243877	iron
0.6577633642	potential
0.6575328683	norepinephrine
0.6573269070	peripheral
0.6569229624	disorder
0.6566483581	reaction
0.6566147308	enzyme
0.6565643769	pain
0.6560907011	nmda
0.6560363906	animal
0.6557532367	wistar
0.6555989041	alcohol
0.6553742180	small
0.6553298127	multiple
0.6552602015	nephropathy
0.6549208405	progressive
0.6548335685	phase
0.6547855121	anaesthesia
0.6547441750	prevention
0.6546618983	levodopa
0.6545725220	microg 0.5 microl
0.6543484710	anesthetic
0.6543484710	reactive
0.6538730225	systemic
0.6534422644	hypotension
0.6534259575	hiv
0.6531953935	life
0.6530875924	water
0.6530795418	ribavirin
0.6529132422	carboplatin
0.6526806706	mg kg i.p
0.6526677956	inhibitors
0.6525158982	venous
0.6523627188	movement
0.6522234991	penicillamine
0.6515320621	binding
0.6515320621	amnesia
0.6514696899	frequency
0.6509885219	total
0.6507429879	diabetic
0.6507309303	specific
0.6505775576	protein
0.6503209812	tests
0.6501170591	angiotensin
0.6499999688	prostate
0.6499999688	gene
0.6496773295	doxorubicin
0.6493524620	atrophy
0.6493524620	deprivation
0.6493524620	synthase
0.6493272010	treated animals
0.6491978524	oral
0.6490130628	ischemia
0.6490010000	arterial
0.6488384644	vivo
0.6487818575	antigen
0.6483375076	output
0.6480734398	temporal
0.6478446899	activation
0.6478303290	male
0.6477723495	urinary
0.6476130359	significant differences
0.6473712309	parkinson
0.6471630598	haloperidol
0.6469085225	resistance
0.6469085225	microscopy
0.6468894757	primary
0.6467473297	induction
0.6467434545	short
0.6467409912	free
0.6467120243	liver
0.6466249542	conversion
0.6466127522	arrhythmia
0.6464184491	proteinuria
0.6464184491	repeated
0.6464184491	cisapride
0.6464184491	verapamil
0.6463392676	daily
0.6463364145	convulsions
0.6462777714	oral administration
0.6461999491	neuroleptic induced
0.6458241865	site
0.6458241865	opioid
0.6458241865	subcutaneous
0.6458241865	pathway
0.6456251813	end
0.6452079492	transplant
0.6447857000	similar
0.6445753214	tumor
0.6444409133	young
0.6442988811	children
0.6434632619	dyskinesia
0.6434395015	fluoxetine
0.6433528404	myocardial
0.6433246272	sodium
0.6425478461	food
0.6425415669	mass
0.6423903289	data
0.6419928325	hypertensive
0.6419524085	association
0.6415720796	selective
0.6412066486	metabolism
0.6412066486	aspartate
0.6412066486	inhibitory
0.6410640380	impaired
0.6405455030	pathways
0.6405455030	necrosis
0.6397352928	muscular
0.6397352928	medulla
0.6397323600	warfarin
0.6395923338	timolol
0.6393495096	defect
0.6393495096	hippocampal
0.6392076306	occlusion
0.6391001210	injury
0.6388345949	half
0.6380923821	apomorphine
0.6380535347	sleep
0.6373630521	aortic
0.6371819999	case reports
0.6364270428	procedure
0.6364001908	steroids
0.6362886116	high dose
0.6361987083	steroid
0.6358241191	hypertension
0.6357546378	reversible
0.6354912952	receptor agonist
0.6354863522	seizure
0.6354172765	tolerability
0.6353084763	alterations
0.6352532724	controlled trial
0.6347849777	beta
0.6346989937	aim
0.6346399833	lower
0.6345287223	metoprolol
0.6344259258	nonsteroidal
0.6340856626	subsequent
0.6340263037	fenoldopam
0.6340263037	isoniazid
0.6337794599	diazepam
0.6337764673	interaction
0.6337732613	reports
0.6334942348	involvement
0.6333818228	bilateral
0.6333757152	volume
0.6330581836	agonist
0.6328914826	gentamicin
0.6328822055	average
0.6327775660	cardiotoxicity
0.6321267591	adriamycin
0.6321007386	continuous
0.6319804770	endothelial
0.6319713889	intravenous
0.6317633717	model
0.6315625633	akathisia
0.6309410085	ciprofloxacin
0.6309410085	prolongation
0.6309410085	methadone
0.6309410085	rapid
0.6309410085	parkinsonism
0.6306145982	transplantation
0.6305482262	metformin
0.6303465004	antidepressant
0.6303465004	emergency
0.6299949205	formation
0.6299949205	mechanical
0.6299949205	intervals
0.6299682215	amphetamine
0.6298954854	degree
0.6298580952	comparison
0.6297575093	nerve
0.6296961802	paclitaxel
0.6296832367	safety
0.6295322373	conventional
0.6295046776	cyclophosphamide
0.6294855562	widely
0.6294783827	naloxone
0.6294783827	initial
0.6294783827	conscious
0.6293764622	earlier
0.6292817412	diuretic
0.6287606329	median
0.6287217440	nephrotoxic
0.6284358561	randomly
0.6283953387	rat
0.6283815653	status
0.6282253634	blocker
0.6281134469	microl
0.6280747563	dexamethasone
0.6279769620	iv
0.6274222719	oxytocin
0.6274222719	maximal
0.6271522229	correlated
0.6271121253	adrenergic
0.6269857191	dose dependent
0.6268029995	efficacy
0.6267792944	heparin
0.6267080654	ethambutol
0.6265405278	tolerance
0.6263371392	growth
0.6259372113	risperidone
0.6258664130	efficacy and safety
0.6254412444	complete
0.6252674497	enhanced
0.6252624355	dexrazoxane
0.6252624355	vancomycin
0.6252624355	topical
0.6252624355	lovastatin
0.6252624355	sirolimus
0.6250627556	peak
0.6249985193	visual
0.6246991056	increases
0.6244999503	ng
0.6238061927	melatonin
0.6238061927	symptomatic
0.6238061927	subsequently
0.6238061927	methamphetamine
0.6237901587	dysfunction
0.6236601793	map
0.6235187171	immediately
0.6234195249	sedation
0.6233782151	diagnosis
0.6230927364	odds
0.6229565636	pretreatment
0.6227658799	light
0.6226585389	protective
0.6224805464	channel
0.6224325647	receive
0.6224312830	chest
0.6224312830	chain
0.6223313718	aspirin
0.6222879600	combination
0.6222155326	type
0.6221429753	bupivacaine
0.6221429753	ifosfamide
0.6221369649	design
0.6219567147	cocaine
0.6218898706	report
0.6218473579	cardiovascular
0.6218203378	high
0.6217931520	structural
0.6217931520	etoricoxib
0.6217107280	muscle
0.6216980948	urine
0.6216915713	ammonia
0.6215455563	cardiomyopathy
0.6213749850	recently
0.6213736137	tomography
0.6213167464	tumors
0.6206430958	micrograms
0.6197962469	prolonged
0.6197027485	neurotoxicity
0.6195850972	significantly lower
0.6195236444	elderly
0.6195067939	adverse
0.6193976868	transient
0.6191815254	hepatotoxicity
0.6191157800	fatal
0.6190087620	amiodarone
0.6189575379	central
0.6189547420	cerebral
0.6189092998	ii
0.6187516818	ventricular
0.6186173473	rise
0.6186152990	lesions
0.6186019534	human
0.6185501893	nephrotic
0.6184530694	midazolam
0.6182928775	nephrotoxicity
0.6181035205	stimulation
0.6178953938	neurons
0.6178105245	hepatic
0.6174892920	models
0.6173960027	vessels
0.6170069736	behavior
0.6168162521	common
0.6167667480	angioedema
0.6167248813	experimental
0.6166556343	coronary
0.6162804468	surgery
0.6160150612	findings
0.6160147395	behavioral
0.6159770953	fraction
0.6159321026	receptor
0.6155949289	assessed
0.6155689007	women
0.6154797317	quantitative
0.6152814678	hemorrhagic
0.6152770493	tachycardia
0.6150089684	mortality
0.6149922255	animals
0.6149110982	reserpine
0.6147247980	fetal
0.6147247980	captopril
0.6147247980	echocardiography
0.6147247980	production
0.6147247980	monitoring
0.6147247980	attenuated
0.6146792386	previous
0.6144178614	positive
0.6143816471	level
0.6143102940	contrast
0.6140686497	addition
0.6140649802	population
0.6140146873	signs
0.6139416748	produced
0.6139146543	double
0.6138424685	factors
0.6136586889	ocular
0.6136586889	sensitivity
0.6128431945	spinal
0.6128106177	enalapril
0.6127958959	brain
0.6127846573	acute
0.6127616960	pre
0.6127616960	hypokalemia
0.6127616960	caffeine
0.6126747342	analysis
0.6125443483	users
0.6123947404	mg kg
0.6123496533	trial
0.6121619148	dexmedetomidine
0.6118414633	ketamine
0.6117844454	biochemical
0.6117212212	myopathy
0.6115405352	therapeutic
0.6111169147	inhibitor
0.6111041849	evaluation
0.6109789649	myocarditis
0.6109789649	indomethacin
0.6109789649	hemoglobin
0.6109789649	aggregation
0.6109789649	valsartan
0.6109176302	suprofen
0.6109176302	dextran
0.6105397355	hour
0.6101881163	presented
0.6099703281	qt
0.6098374288	cancer
0.6098022457	severe
0.6096909554	avoidance
0.6094662837	laboratory
0.6093782622	concentration
0.6093730689	injections
0.6092963590	acid
0.6091728904	malignant
0.6090170859	postoperative
0.6086147085	reduced
0.6085014443	epileptic
0.6084887511	recent
0.6084684055	block
0.6083812238	flow
0.6078234331	failure
0.6075971749	mechanisms
0.6074032300	hepatitis
0.6074026441	fluconazole
0.6074026441	heavy
0.6074026441	amisulpride
0.6074026441	sulindac
0.6074026441	hematologic
0.6074026441	persistent
0.6074026441	lethal
0.6074026441	deaths
0.6074026441	adjusted
0.6074026441	thromboembolism
0.6074026441	surgical
0.6074026441	influence
0.6072451057	ht
0.6071344909	force
0.6071269042	hr
0.6071220217	antagonist
0.6069927190	nsaids
0.6069822034	undergoing
0.6067147040	enflurane
0.6067147040	halothane
0.6067147040	cholestatic
0.6067147040	limiting
0.6067147040	detection
0.6067147040	brainstem
0.6067147040	minor
0.6067147040	experiments
0.6067147040	compound
0.6067147040	screening
0.6067147040	aggressive
0.6067147040	penicillin
0.6067147040	isoproterenol
0.6064852277	implicated
0.6064852277	aware
0.6063171756	relationship
0.6062228721	cholinergic
0.6061711715	serum
0.6061685802	randomised
0.6054091999	severity
0.6051256128	spontaneous
0.6050949184	left
0.6049769320	blood
0.6048037746	catalepsy
0.6047520373	test
0.6046597131	ml
0.6046224486	electron
0.6044639695	concentrations
0.6043060861	led
0.6043060861	characterized
0.6038363554	tacrine
0.6038363554	hypoxia
0.6037671304	higher
0.6037637642	receiving
0.6035990958	randomized
0.6033426965	pilocarpine
0.6030732197	passive
0.6030482948	vascular
0.6029616676	improvement
0.6026328728	measures
0.6022453167	versus
0.6017919659	neuropathy
0.6017342316	metoclopramide
0.6017342316	cibenzoline
0.6017342316	hyperalgesia
0.6016608085	tobramycin
0.6016608085	exercise
0.6016608085	refractory
0.6016608085	extensive
0.6016608085	open
0.6016608085	toxicities
0.6016038906	motor
0.6011853104	events
0.6011853104	prior
0.6010676329	simultaneously
0.6008283849	observations
0.6007504368	combined
0.6007326421	prospective
0.6006423311	field
0.6005678020	calcium
0.6003913915	low
0.6002888269	anemia
0.6002733957	stress
0.6002499947	kidney
0.6001471941	symptoms
0.6000959057	bladder
0.6000018150	findings suggest
0.5998091852	additional
0.5996594224	mediated
0.5996118080	remifentanil
0.5996118080	gastrointestinal
0.5995806871	syndrome
0.5993562020	cell
0.5983669277	tolerated
0.5980366788	desipramine
0.5979343631	mild
0.5978420482	striatum
0.5975768215	respiratory
0.5975066153	dynamic
0.5973004125	mechanism
0.5972996292	current
0.5970630794	succinylcholine
0.5970291250	mm
0.5969129488	diltiazem
0.5969129488	experience
0.5969129488	post
0.5965501411	multicenter
0.5963909109	hiccups
0.5963909109	latency
0.5963909109	dobutamine
0.5963909109	carbamazepine
0.5963909109	large
0.5963909109	underlying
0.5963909109	information
0.5963909109	initially
0.5962865075	hallucinations
0.5959413804	authors
0.5959394462	cortical
0.5955242767	discontinuation
0.5953985743	impairment
0.5951918592	rigidity
0.5947616165	review
0.5946787349	pretreated
0.5943142408	controlled
0.5941362920	chronic
0.5938566103	involved
0.5932041855	based
0.5929646364	placebo
0.5925493381	infusion
0.5923697209	men
0.5922912863	drugs
0.5921700829	migraine
0.5921233363	flumazenil
0.5918869542	appears
0.5918039291	cardiac
0.5916132160	method
0.5908571704	aura
0.5906007264	amb
0.5904974555	tamoxifen
0.5904394158	d2
0.5903641508	i.v
0.5902733492	highly
0.5902733492	isoflurane
0.5902733492	hyperprolactinemia
0.5902733492	limited
0.5901760897	action
0.5899304918	studied
0.5898635523	i.p
0.5898614307	control
0.5892180302	enac
0.5890828220	absence
0.5890828220	consistent
0.5889604283	mesna
0.5887108946	approximately
0.5886798470	factor
0.5886334901	mice
0.5883652135	damage
0.5880100840	single
0.5879555853	case
0.5878605769	renal
0.5878241551	auditory
0.5873345727	eps
0.5873048607	plasma
0.5868768784	memory
0.5867720494	significant
0.5866406985	clinical
0.5863422612	related
0.5862754631	greater
0.5854760104	effective
0.5852563397	protection
0.5851610720	groups
0.5851586293	adrenaline
0.5848682634	neurological
0.5848682634	altered
0.5847965048	hormone
0.5843758381	treated rats
0.5835995921	incidence
0.5834877103	measurements
0.5834255938	m2
0.5831129696	chloride
0.5829127618	drug
0.5828868029	tdp
0.5822525017	heart
0.5820080387	propranolol
0.5820080387	overdose
0.5820080387	cumulative
0.5820049624	arthritis
0.5815427665	weight
0.5812883630	bone
0.5808830322	dependent
0.5807787531	chf
0.5797859159	loss
0.5796852383	nausea
0.5796319893	degeneration
0.5794239335	administered
0.5790077166	cells
0.5788691233	accumulation
0.5786124890	occurrence
0.5781287705	decrease
0.5777668325	blockade
0.5777668325	tacrolimus
0.5776546122	setting
0.5766530459	analgesic
0.5766530459	functional
0.5766530459	medications
0.5762802771	onset
0.5759778983	occurred
0.5759063512	bp
0.5753364171	words
0.5752312247	adult
0.5746805855	myoclonus
0.5746480433	days
0.5746100386	body
0.5745846956	nicotine
0.5744906399	expression
0.5744682544	study
0.5744605369	intake
0.5744605369	dosing
0.5744605369	ischemic
0.5744082371	cm
0.5743656227	achieved
0.5740645197	function
0.5738902197	yohimbine
0.5738902197	generally
0.5738902197	concomitant
0.5738902197	late
0.5735216140	agent
0.5734418868	cimetidine
0.5733490693	decreases
0.5731394309	infection
0.5731394309	continued
0.5731394309	resulting
0.5731394309	required
0.5731394309	induces
0.5731394309	analyzed
0.5731394309	psychosis
0.5731394309	adrenoceptor
0.5731394309	antagonists
0.5729166715	inos
0.5728443484	caused
0.5728086036	increased
0.5727366939	main
0.5726628905	cases
0.5726258608	increase
0.5725700056	history
0.5723569793	acetaminophen
0.5722722614	perfusion
0.5721281912	amlodipine
0.5720523751	aminonucleoside
0.5720460696	suppressed
0.5719829306	epinephrine
0.5719519233	morphine
0.5715510587	bupropion
0.5715356733	reactions
0.5715356733	sustained
0.5715356733	clinically
0.5714993889	outcome
0.5713974120	na
0.5712846360	ip
0.5710912433	evidence
0.5710753824	cyp
0.5705361949	min
0.5704671815	change
0.5701366153	riha
0.5701117075	major
0.5701117075	apoptosis
0.5701052674	pressure
0.5701007840	age
0.5697035757	important
0.5694507086	patient
0.5694299259	statistically
0.5691177829	suggest
0.5689981321	solution
0.5689981321	antibody
0.5686877972	baseline
0.5686279107	microg
0.5681118345	zidovudine
0.5681118345	contralateral
0.5680706537	parkinsonian
0.5679166905	disease
0.5678843795	role
0.5677354470	vehicle
0.5674825162	pod
0.5674699950	documented
0.5674521485	discussion
0.5673198995	tissue
0.5670603576	abnormal
0.5670603576	glutamate
0.5669654434	frequently
0.5669654434	inhibited
0.5669654434	support
0.5669654434	ability
0.5669654434	maintenance
0.5669654434	detected
0.5669629917	tubular
0.5666985142	inhibition
0.5665623083	nrf2
0.5663477239	mrna
0.5663155315	methylprednisolone
0.5662442224	pattern
0.5661850497	collected
0.5661850497	mmol
0.5661850497	iodixanol
0.5661850497	segment
0.5661697117	conduction
0.5661697117	diastolic
0.5661697117	correlation
0.5661697117	release
0.5661697117	died
0.5661069311	paracetamol
0.5660887618	woman
0.5659231776	taking
0.5659231776	diet
0.5654995639	nag
0.5653352375	micturition
0.5653352375	fold
0.5653352375	propofol
0.5652569910	cycle
0.5652569910	cost
0.5652569910	sites
0.5652569910	trihexyphenidyl
0.5652569910	antigens
0.5652569910	alfentanil
0.5652569910	cholinesterase
0.5652336634	prevent
0.5652336634	safe
0.5652336634	complication
0.5651892350	marked
0.5651892350	increasing
0.5651778584	optic
0.5651182348	spasm
0.5651182348	started
0.5651182348	locomotor
0.5651182348	maximum
0.5651182348	elevation
0.5651182348	confirmed
0.5651182348	pallidotomy
0.5651182348	monitored
0.5651182348	demonstrate
0.5645039092	hemolytic
0.5644707563	group
0.5644536157	rats
0.5640619341	ca
0.5635427853	toxicity
0.5631817576	weeks
0.5627511754	mtdna
0.5627169612	scopolamine
0.5626864910	present
0.5622955508	word
0.5622874239	response
0.5621440939	task
0.5621440939	db
0.5619532344	alf
0.5619532344	pregs
0.5617897832	uveitis
0.5617897832	overflow
0.5617897832	dl
0.5617897832	deficits
0.5617897832	interferon
0.5617897832	channels
0.5617897832	count
0.5617897832	highest
0.5617383641	levels
0.5616638300	rubella
0.5615913471	duration
0.5612352522	risk
0.5609238649	pd
0.5605252340	glaucoma
0.5605252340	recall
0.5602811647	target
0.5602647225	differences
0.5602419839	interval
0.5601967068	bradycardia
0.5601967068	potent
0.5599962300	thirty
0.5599515514	rate
0.5598765209	injection
0.5597015341	produce
0.5597015341	occurring
0.5597015341	reduce
0.5597015341	possibly
0.5597015341	hyperactivity
0.5597015341	coma
0.5597015341	recipients
0.5597015341	vasculitis
0.5597015341	suggesting
0.5597015341	subject
0.5597015341	rapidly
0.5597015341	diagnosed
0.5597015341	enzymes
0.5597015341	extent
0.5597015341	intensity
0.5595121604	ouabain
0.5595121604	proliferation
0.5595121604	pressor
0.5595121604	supplementation
0.5595121604	neuronal
0.5595121604	delirium
0.5595121604	isolated
0.5595121604	learning
0.5595121604	hydrochloride
0.5595121604	infants
0.5591305219	potassium
0.5590689902	dopaminergic
0.5590689902	noted
0.5590689902	episodes
0.5589148702	pan
0.5587983623	hypercalcemia
0.5587983623	netilmicin
0.5587983623	pathological
0.5587983623	potentiated
0.5587983623	cyclosporine
0.5587983623	clearance
0.5587983623	alternative
0.5587983623	improves
0.5587983623	conditions
0.5587983623	metabolites
0.5587983623	occurs
0.5587983623	develop
0.5587983623	consisted
0.5587983623	ingestion
0.5587983623	observation
0.5587983623	returned
0.5587983623	younger
0.5587983623	outcomes
0.5587983623	applied
0.5587983623	pathogenesis
0.5587983623	distinct
0.5587983623	morbidity
0.5587983623	regions
0.5587983623	derivative
0.5587983623	respect
0.5587983623	functions
0.5587983623	completed
0.5587983623	generalized
0.5587983623	idiopathic
0.5587983623	needed
0.5587983623	process
0.5587983623	pediatric
0.5587983623	terms
0.5587983623	fixed
0.5587983623	bolus
0.5587983623	differ
0.5587983623	schizophrenia
0.5587983623	reviewed
0.5587983623	focal
0.5587983623	procedures
0.5587983623	phenomenon
0.5587983623	maintained
0.5587983623	represent
0.5587983623	starting
0.5587983623	child
0.5587285851	randomly assigned to
0.5586499322	moderate
0.5585690695	threshold
0.5585602087	artery
0.5584870013	azt
0.5581219579	med
0.5579323198	resolution
0.5579323198	fed
0.5579323198	schedule
0.5579323198	testosterone
0.5579323198	approach
0.5579323198	concluded
0.5579323198	form
0.5579323198	blocking
0.5579323198	actions
0.5579323198	indicating
0.5579323198	monotherapy
0.5579323198	beneficial
0.5579323198	methyl
0.5579323198	include
0.5579323198	survival
0.5579323198	markedly
0.5579323198	withdrawal
0.5579323198	manner
0.5579323198	provide
0.5579323198	affect
0.5579323198	remains
0.5579323198	consecutive
0.5579323198	cellular
0.5579323198	unchanged
0.5579323198	hypertrophy
0.5579323198	discussed
0.5579323198	pregnancy
0.5578327881	wk
0.5572051215	results
0.5567164360	wt
0.5558394204	cross
0.5558394204	tremor
0.5558394204	iohexol
0.5558394204	scores
0.5558369317	da
0.5557332926	den
0.5557218330	beta1
0.5557218330	dilevalol
0.5556101639	commonly
0.5556101639	discontinued
0.5556101639	completely
0.5556101639	prevented
0.5556101639	induce
0.5556101639	angiography
0.5556101639	female
0.5550188563	iop
0.5549514763	percent
0.5548095897	activity
0.5547936849	stz
0.5547936849	gad
0.5543068422	group ii
0.5541057381	vip
0.5540318240	complications
0.5539487624	significantly reduced
0.5536930037	anesthetics
0.5536930037	features
0.5534712180	chemotherapy
0.5529954608	wall
0.5529954608	reflex
0.5529954608	consumption
0.5529954608	protocol
0.5529954608	content
0.5528717647	early
0.5522819680	minutes
0.5519411233	active
0.5519411233	remained
0.5519125588	observed
0.5516458247	ra
0.5514632683	apical
0.5514632683	quetiapine
0.5514632683	orally
0.5514632683	condition
0.5514632683	defined
0.5514632683	comparable
0.5514632683	reduces
0.5514632683	unclear
0.5514632683	recovery
0.5514632683	prazosin
0.5514632683	conclude
0.5511899703	rates
0.5511899703	range
0.5504083783	result
0.5504072302	suggested
0.5501311056	obtained
0.5501311056	recorded
0.5499099339	pharmacological
0.5499099339	treatments
0.5499099339	cis
0.5499099339	cisplatin
0.5499099339	intrathecal
0.5499099339	inflammation
0.5499099339	terbutaline
0.5499099339	estimated
0.5499099339	secretion
0.5499099339	fluvoxamine
0.5499099339	hypotensive
0.5499099339	untreated
0.5499099339	s.c
0.5499099339	spontaneously
0.5499099339	volunteers
0.5499099339	basis
0.5499099339	levofloxacin
0.5499099339	stenosis
0.5499099339	selected
0.5499099339	region
0.5499099339	designed
0.5499099339	areas
0.5499099339	disappeared
0.5499099339	play
0.5499099339	unknown
0.5499099339	presentation
0.5499099339	potentially
0.5499099339	recommended
0.5499099339	complex
0.5496939796	vpa
0.5490455419	excretion
0.5490455419	lidocaine
0.5488882865	resulted
0.5485025474	significantly
0.5484858860	literature
0.5483965033	meth
0.5481362666	abnormalities
0.5481362666	difference
0.5481362666	responses
0.5479346469	breast
0.5479116165	reported
0.5472367991	samples
0.5471658508	reduction
0.5469802936	reuptake
0.5469802936	accompanied
0.5469802936	humans
0.5469802936	treat
0.5469802936	failed
0.5468645825	ci
0.5464627737	myalgia
0.5462490291	tested
0.5461111484	background
0.5460471424	eyes
0.5458265011	doses
0.5457574682	partial
0.5455248986	ntg
0.5454349876	long
0.5454134568	dyskinesias
0.5453695286	cs
0.5449656738	reversed
0.5449656738	identified
0.5449656738	rare
0.5449656738	shown
0.5446572163	csa
0.5445722952	elevated
0.5445319533	oct
0.5444951604	developed
0.5444158132	development
0.5443580360	therapy
0.5443548138	experienced
0.5443548138	hours
0.5439211598	objectives
0.5428722022	parp
0.5428366915	nervous system
0.5426016731	purpose
0.5419893297	patients
0.5418730678	lesion
0.5418140472	injected
0.5412006098	improved
0.5412006098	advanced
0.5412006098	conducted
0.5412006098	exhibited
0.5412006098	movements
0.5412006098	resolved
0.5412006098	underwent
0.5408329251	oab
0.5407350925	objective
0.5402208118	dosage
0.5401376086	dose
0.5398296282	lead
0.5398296282	values
0.5387862939	af
0.5387862939	sd
0.5382554399	effect
0.5382067044	times
0.5381047948	score
0.5379859865	cord
0.5377097133	arrest
0.5371344712	medication
0.5371344712	affected
0.5371344712	parameters
0.5370260582	considered
0.5370260582	stage
0.5369896526	vitro
0.5369896526	appeared
0.5369896526	suggests
0.5365001173	shr
0.5363302449	treatment
0.5361497567	dox
0.5359843915	determined
0.5359843915	previously
0.5354806036	healthy
0.5352533309	agents
0.5352533309	included
0.5346695701	ecg
0.5346667790	controls
0.5346033252	mdma
0.5342586776	adr
0.5336392361	bis
0.5320913729	toxic
0.5320292613	torsade
0.5320292613	oxidative
0.5320292613	fibrillation
0.5320292613	reversal
0.5319881273	evaluate
0.5319881273	blind
0.5317182674	administration
0.5314166314	cp
0.5313547788	mk
0.5311378667	lithium therapy
0.5307909500	conclusions
0.5306239692	iii
0.5305484772	compared
0.5303900781	conclusion
0.5303855865	exposure
0.5303748100	evaluated
0.5301524418	receptors
0.5297384463	examined
0.5295870912	performed
0.5295396165	measured
0.5295396165	revealed
0.5293085446	demonstrated
0.5289641772	subjects
0.5287384463	dogs
0.5287384463	investigated
0.5279983702	pb
0.5279983702	lid
0.5279824168	alpha
0.5274857751	including
0.5269305002	effects
0.5266252341	gaba
0.5246648330	saline
0.5239203133	infarction
0.5239203133	initiation
0.5215215457	sm
0.5206105794	neuroleptic
0.5196065565	methods
0.5195570094	treated
0.5194993122	week
0.5177187667	induced
0.5159574072	st
0.5154778285	puromycin
0.5154778285	investigate
0.5130144484	seizures
0.5096440956	normal
0.5071406767	period
0.5066810999	studies
0.5059724740	months
0.5059132743	kg
0.5040596184	decreased
0.5017358343	patients undergoing
0.5010583003	follow
0.4994290860	years
0.4975533905	received
0.4973996987	mg
0.4948243391	showed
0.4942155273	95 confidence interval
0.4907595629	determine
0.4848992570	d penicillamine
0.4831325788	number
0.4800949782	vitamin c
0.4772503315	5 fu
0.4768058911	levodopa induced
0.4757537240	term
0.4639129516	follow up
0.4636928868	hepatitis b
0.4584753506	de pointes
0.4535929425	x
0.4477328873	95 ci
0.4443584856	results suggest
0.4318335565	value
0.4300282998	m
0.4289707657	does
0.4276568880	new
0.4250529167	second
0.4181157281	t
0.4169111596	right
0.4150967569	novel
0.4088967367	possible
0.4065670771	48
0.4058536283	seems
0.4058323819	last
0.4031111915	five
0.4024960912	c
0.4020091348	twice
0.4010863155	such
0.3959355681	h
0.3951727735	first
0.3938598374	acute liver
0.3924010848	0.01
0.3921138121	b
0.3919422376	most
0.3894484443	80
0.3849323480	de
0.3814596788	d
0.3813658511	n
0.3778283900	l
0.3726974602	95 confidence
0.3718112684	side effects
0.3706790476	various
0.3706594000	200
0.3704345048	0.001
0.3692702968	seen
0.3685600820	co
0.3678571571	s
0.3667927004	p
0.3666298624	two
0.3665993581	significantly increased
0.3652495039	serious
0.3651473567	throughout
0.3651473567	taken
0.3648696061	overall
0.3644360103	little
0.3636372251	her
0.3617561793	both
0.3600121355	corresponding
0.3597268181	they
0.3590736156	since
0.3589860671	time
0.3586861832	well tolerated
0.3582762644	patient developed
0.3582399730	none
0.3571953581	until
0.3569537103	cause
0.3568488884	these
0.3565585806	sixty
0.3564441820	0.05
0.3563978518	ten
0.3563978518	she
0.3562801988	before
0.3561507693	eight
0.3558356196	indicate
0.3532163520	he
0.3531897101	system
0.3529272353	his
0.3529272353	therefore
0.3523772440	all
0.3520675269	despite
0.3517957612	5 ht
0.3509750178	even
0.3506473394	24
0.3494638389	another
0.3494638389	many
0.3489468415	one
0.3486608454	day
0.3484137069	14
0.3478401392	changes
0.3478029912	per
0.3470909563	course
0.3470291177	within
0.3470167753	less
0.3463328223	used
0.3462522991	twice daily
0.3460027144	followed
0.3455121746	this
0.3453544132	i
0.3451319973	in
0.3438687516	neither
0.3438685514	found
0.3429411423	well
0.3418331804	after
0.3417471242	7
0.3413171076	often
0.3413171076	few
0.3413080130	several
0.3409430446	third
0.3408036083	nine
0.3407759273	least
0.3404486727	forty
0.3403165538	up
0.3402843537	some
0.3401706563	here
0.3400792363	0.5
0.3399382412	further
0.3394950826	seven
0.3390267085	year
0.3389898972	off
0.3388427377	no
0.3385170057	at
0.3383524346	use
0.3380325117	100
0.3378460641	95
0.3377967795	the
0.3374089259	thus
0.3374015702	associated
0.3373628001	did
0.3371782374	side
0.3371543070	more
0.3367939768	if
0.3360718305	the present study
0.3360265191	k
0.3358921977	moreover
0.3356962233	e
0.3346427627	as
0.3344396429	among
0.3342005303	r
0.3334861560	50
0.3334248902	greater than
0.3332876953	very
0.3332876953	above
0.3327488904	mean
0.3327280433	30
0.3324438609	six
0.3324019163	because
0.3317865648	g
0.3314699492	between
0.3313473996	on
0.3313007484	whereas
0.3310596651	old
0.3306006135	=
0.3303885369	a
0.3300322355	twenty
0.3293604829	furthermore
0.3285156606	6
0.3282294052	an
0.3260608548	10
0.3260022060	four
0.3254484621	available
0.3254484621	so
0.3254484621	via
0.3253367306	20
0.3246796317	out
0.3227020787	57
0.3211217748	24 hour
0.3211031673	32
0.3204712572	our
0.3197065259	than
0.3196375434	following
0.3195545708	same
0.3194527130	while
0.3194527130	three
0.3188645845	to
0.3186791221	29
0.3184488201	31
0.3152938815	using
0.3137395275	but
0.3114785523	although
0.3102729071	there
0.3102103778	due
0.3100671608	during
0.3099350456	by
0.3096399725	19
0.3095146951	any
0.3095146951	under
0.3094410814	whom
0.3094410814	better
0.3093916412	p 0.05
0.3092717737	12
0.3092317681	their
0.3089540709	22
0.3087874065	for
0.3079799400	33
0.3078631446	26
0.3076937334	when
0.3076008085	each
0.3075765059	35
0.3074176866	150
0.3074176866	0.3
0.3074131332	3.8
0.3074131332	would
0.3074131332	300
0.3074131332	need
0.3074131332	clearly
0.3074131332	done
0.3071141266	41
0.3071141266	67
0.3067014173	of
0.3062646951	whether
0.3062333910	however
0.3060712337	23
0.3060712337	45
0.3058366685	1.5
0.3051405740	given
0.3044576783	it
0.3040625652	relationship between
0.3039788946	over
0.3036741947	5
0.3028055567	once
0.3028055567	every
0.3025313475	not
0.3020198122	17
0.3015110556	with
0.3014396024	65
0.3014396024	27
0.3014396024	then
0.3014396024	being
0.3013634934	year old woman
0.3011714115	25
0.3001090115	from
0.2994834730	1.0
0.2990547600	side effect
0.2990089493	later
0.2990089493	describe
0.2990089493	0.1
0.2989390642	16
0.2987966851	especially
0.2981844302	indicated
0.2981844302	nor
0.2978522587	13
0.2974985718	still
0.2974985718	mainly
0.2974985718	made
0.2961484037	particularly
0.2961484037	801
0.2961484037	probably
0.2961484037	where
0.2961484037	120
0.2961484037	relatively
0.2961484037	necessary
0.2960276812	0.2
0.2956118856	0.6
0.2956118856	almost
0.2952764607	1
0.2952630904	part
0.2952630904	90
0.2952630904	useful
0.2952630904	might
0.2950890958	likely
0.2950851397	plus
0.2950851397	show
0.2949581051	250
0.2948186575	40
0.2947786513	2.0
0.2947487641	through
0.2944677732	known
0.2940597826	we
0.2932695323	those
0.2929222042	about
0.2917351166	9
0.2917061619	non
0.2915788268	500
0.2911335467	containing
0.2911335467	18
0.2911335467	causes
0.2910426376	2.5
0.2897045713	0
0.2885685585	0.5 microl
0.2882852688	vs
0.2875773871	alone
0.2869068685	single dose
0.2860587200	21
0.2851829350	like
0.2840972100	11
0.2827450891	could
0.2826504586	different
0.2824257253	old woman
0.2823917768	4
0.2823563113	other
0.2822984641	also
0.2821094326	elderly patients
0.2818566377	60
0.2818210906	induced convulsions
0.2814393134	2
0.2800347398	+
0.2798103901	into
0.2796379434	described
0.2790406990	its
0.2780691298	either
0.2776093920	significant decrease in
0.2775603901	against
0.2772724243	year old
0.2763730718	200 mg
0.2761608782	8
0.2761495896	should
0.2746627476	these results suggest
0.2734668630	15
0.2721106240	mg m
0.2700336931	respectively
0.2698075849	widely used
0.2694513950	can
0.2680228235	only
0.2670228235	without
0.2667293355	n =
0.2653411199	which
0.2653411199	has
0.2645585906	48 h
0.2642813680	3
0.2594648585	and
0.2591610123	been
0.2591610123	have
0.2591610123	who
0.2586118320	are
0.2576118320	had
0.2576118320	may
0.2573839617	or
0.2569399101	kg i.v
0.2566539137	the placebo group
0.2560466146	be
0.2555582425	is
0.2555582425	was
0.2555582425	that
0.2555582425	were
0.2538838697	min before
0.2528483699	x 10
0.2479653377	year old man
0.2448520078	as well as
0.2415585410	haloperidol induced
0.2399861845	p 0.001
0.2365143025	heparin induced
0.2349967870	results indicate
0.2344463679	s disease
0.2338945956	these findings
0.2302626099	p 0.01
0.2300456783	100 mg
0.2266086450	differences between
0.2263576964	7 days
0.2253940840	responsible for
0.2231743979	80 mg
0.2176021003	to assess
0.2168056407	a single dose
0.2158384599	acute renal
0.2149663714	association between
0.2146915242	old man
0.2136094469	0.5 mg
0.2119996651	patients receiving
0.2107047963	a case report
0.2100239970	an important
0.2063145297	14 days
0.2051031568	the most common
0.2025988054	did not
0.2024894131	mg day
0.2016726211	induced hypotension
0.1981320257	present study
0.1970762151	regulation of
0.1958718876	on pod
0.1904337357	treated patients
0.1903113884	drug induced
0.1873129793	p =
0.1855595641	p less than
0.1848016775	compared with
0.1827938083	characterized by
0.1825080776	no evidence
0.1821409496	assigned to
0.1800620959	30 min
0.1800046902	does not
0.1795766144	at least
0.1788159332	able to
0.1763980701	doxorubicin induced
0.1746362095	control group
0.1698659722	based on
0.1673076628	24 h
0.1660586690	in order to
0.1626319590	both groups
0.1611651167	caused by
0.1596365332	patients treated
0.1576147624	patients developed
0.1553440228	time course
0.1544882731	less than 0.05
0.1541842719	6 weeks
0.1498532402	before and after
0.1494964548	patients treated with
0.1484537708	the control group
0.1483168396	a dose dependent
0.1479403202	group b
0.1479207828	according to
0.1478841581	the efficacy and
0.1476148454	accompanied by
0.1460557917	the presence of
0.1453933158	placebo group
0.1413002026	such as
0.1391948757	higher than
0.1378680137	the presence
0.1378345690	to determine
0.1357157034	50 mg kg
0.1355705134	pretreated with
0.1344410731	this study
0.1340927522	an average
0.1338610118	10 mg kg
0.1331283085	consistent with
0.1326927990	due to
0.1324793309	to evaluate
0.1317004243	treated with
0.1287025946	to investigate
0.1283319701	induced catalepsy
0.1277057438	two groups
0.1272906332	mg per
0.1259350503	a significant decrease
0.1249344892	no significant
0.1248253176	the aim of
0.1247828497	the occurrence of
0.1241109376	led to
0.1236438137	failed to
0.1228459028	immediately after
0.1211176886	associated with
0.1203828204	appears to
0.1176740533	in patients receiving
0.1170733754	50 mg
0.1161802202	per day
0.1161080939	to treat
0.1132216672	less than
0.1108583277	induced by
0.1101959466	the long term
0.1087947606	20 mg
0.1077006018	both drugs
0.1064020299	1 mg kg
0.1053039608	in combination with
0.1051394612	mean arterial
0.1030389538	5 mg kg
0.0994445151	number of
0.0955778924	in humans
0.0950720513	initiation of
0.0908991299	these results
0.0890510474	these data
0.0879559240	the striatum
0.0840213024	5 mg
0.0836192887	patients with
0.0830162120	one patient
0.0814611288	reversal of
0.0806245108	followed by
0.0801569249	but not
0.0790590013	a case of
0.0756491912	seems to
0.0753806665	no effect on
0.0750730252	single dose of
0.0735101889	a patient with
0.0720864669	two cases of
0.0700280876	correlated with
0.0696885495	the development of
0.0684833582	in patients with
0.0683070217	this patient
0.0674545363	resulted in
0.0656136830	the same
0.0625760137	a novel
0.0619689156	doses of
0.0608634611	t +
0.0600059748	the treatment of
0.0593445321	an increase in
0.0578085383	administration of
0.0551653505	the incidence of
0.0548982043	the use of
0.0547300428	treatment with
0.0545583553	mediated by
0.0534665773	the patient
0.0528774007	more than
0.0528506494	compared to
0.0510744822	10 mg
0.0509255833	the effect of
0.0506792331	effect of
0.0501766275	produced by
0.0490913210	effects of
0.0488591182	the procedure
0.0471274659	all patients
0.0468581267	the literature
0.0467639629	in rats
0.0458203201	the effects of
0.0456501367	the role of
0.0453984385	effect on
0.0426823917	secondary to
0.0425591537	a total of
0.0425410964	increase in
0.0418999865	to receive
0.0402611070	two cases
0.0388502525	an effective
0.0388346127	days after
0.0379890840	the number of
0.0375437012	implicated in
0.0363460940	the last
0.0349119548	the administration of
0.0345447009	neurons in
0.0345229023	related to
0.0340455150	at doses
0.0339508680	assessed by
0.0336678252	the number
0.0329072923	the absence of
0.0321245507	decrease in
0.0320094881	a history of
0.0319511517	involved in
0.0314677779	children with
0.0314511517	inhibition of
0.0312107565	a single
0.0311956033	dose of
0.0309890840	the risk of
0.0308415467	the study
0.0302987806	association with
0.0292549781	days of
0.0289997668	a phase
0.0288415467	the rat
0.0288214954	a case
0.0288040594	this case
0.0286143600	the first
0.0284641733	injection of
0.0284577313	presented with
0.0284511517	prevention of
0.0282549781	action of
0.0278214954	the present
0.0278214954	the development
0.0278017484	pretreatment with
0.0276264696	the onset of
0.0273042718	women on
0.0272549781	cells in
0.0271471723	prior to
0.0271424515	an increase
0.0268086312	the current
0.0266888442	rise in
0.0264258768	h after
0.0262833197	course of
0.0260801889	five patients
0.0260614937	aware of
0.0260508548	change in
0.0259280916	evidence of
0.0254926077	reduction in
0.0252677142	loss of
0.0251277779	improvement in
0.0249978864	the hypothesis
0.0245828544	history of
0.0242459233	discontinuation of
0.0240508548	evaluation of
0.0239083628	cases of
0.0238584264	onset of
0.0234728789	case of
0.0232613079	severity of
0.0231458791	effects on
0.0230230659	of treatment with
0.0228415467	in mice
0.0227767752	no effect
0.0227612478	the duration of
0.0227612478	the results of
0.0224926077	incidence of
0.0219881552	combined with
0.0215946373	model of
0.0215621775	absence of
0.0214224590	of patients with
0.0212915968	not significantly
0.0211712197	a prospective
0.0199083628	levels of
0.0198584264	activation of
0.0195744505	duration of
0.0195381552	degree of
0.0191591534	expression of
0.0191236281	this drug
0.0189347069	development of
0.0189083628	observed in
0.0185513002	changes in
0.0184573912	increased from
0.0184448219	risk for
0.0181377859	reduction of
0.0181277779	increases in
0.0181136765	30 mg
0.0177059984	these patients
0.0174936211	an acute
0.0173181573	similar to
0.0168584264	frequency of
0.0168214954	the results
0.0165447009	alterations in
0.0165381552	diagnosis of
0.0165381552	management of
0.0165049781	activity of
0.0163181573	occurred in
0.0158777779	injections of
0.0157812263	a significant
0.0155243296	role of
0.0155243296	role in
0.0154249437	the kidney
0.0154187981	1 mg
0.0153643039	use of
0.0152549781	weeks of
0.0150781552	involvement of
0.0148781552	differences in
0.0148512527	induction of
0.0147743296	rate of
0.0145447009	models of
0.0141545724	in patients
0.0139167738	2 mg
0.0138512527	risk of
0.0137447009	woman with
0.0135447009	assessment of
0.0135447009	review of
0.0135049781	infusion of
0.0134864067	treatment for
0.0128584264	end of
0.0127388972	a history
0.0122549781	mechanism of
0.0121912527	women with
0.0121649781	treatment of
0.0121649781	efficacy of
0.0118101670	a new
0.0116751717	a specific
0.0114249437	the mechanism
0.0111750931	combination with
0.0111750931	aim of
0.0111214954	to control
0.0111112182	in vivo
0.0110077699	the incidence
0.0109716448	therapy for
0.0108584264	studied in
0.0108584264	occurrence of
0.0107888972	a double
0.0105716448	studies of
0.0105714954	a patient
0.0105049781	symptoms of
0.0105049781	analysis of
0.0105049781	toxicity of
0.0105049781	mice with
0.0105049781	patient with
0.0105049781	rats with
0.0105049781	therapy with
0.0105049781	administered to
0.0105049781	reported in
0.0105049781	reported to
0.0104249437	the duration
0.0102549781	function in
0.0102549781	type of
0.0102549781	trial of
0.0102549781	level of
0.0102549781	expression in
0.0102549781	administered in
0.0102549781	mechanisms of
0.0102549781	concentrations of
0.0102549781	concentration of
0.0101497896	found to
0.0100714954	in women
0.0099749437	the occurrence
0.0099249437	in children
0.0095667127	seen in
0.0095269899	time of
0.0091304382	day for
0.0088167127	a possible
0.0088167127	used for
0.0086413078	the right
0.0081869899	found in
0.0081869899	used to
0.0081869899	cause of
0.0078804382	up to
0.0075269899	used in
0.0072769899	the most
